Aushon BioSystems, Inc., a provider of advanced microarray instrumentation and laboratory services for biomarker discovery, development and analysis, has launched new Human multiplex biomarker panels for the quantification of eight biomarkers related to drug-induced kidney damage, or nephrotoxicity. Recent studies identifying biomarkers for kidney injury during pre-clinical testing for certain drugs helped initiate the development of the new panels. Requiring minimal sample volume, the new multiplex biomarker panels address the need for a more rapid, sensitive and accurate method to identify and quantify renal toxicity biomarkers to assist in determining risk.
The Human Nephrotoxicity Panels are validated for analysis of urine samples. The panels were developed using the Aushon SearchLight® protein array technology – a multiplex, sandwich ELISA system based on chemiluminescent or infrared detection of analytes. It features a 3.5 hour protocol that is very similar to protocols for traditional plate-based ELISA kits.
The new multiplex panels include the following biomarkers:
• KIM-1, Clusterin, TIMP-1, VEGF, Trefoil Factor-3 (TFF-3), Osteopontin, EGF, NGAL
Researchers can analyze samples from clinical trials using Aushon’s CLIA-certified sample testing service or conduct the analysis themselves using Aushon’s chemiluminescent biomarker kits and imaging system.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.